TAU PEPTIDE

Reviews peptide compounds acting as tau aggregation inhibitors (TAI), developed through structure-based design and phage display, showing promise as therapeutic candidates for Alzheimer's disease by targeting tau pathology which correlates closely with clinical symptoms.

Comprehensive review of tau-targeting therapies including immunotherapies, post-translational modifications, and aggregation inhibitors, noting that tau shows stronger correlation with symptom severity than amyloid-β, making it a more promising therapeutic target.

DHA acts at multiple steps to reduce beta-amyloid production and moderates kinases that hyperphosphorylate tau protein, potentially slowing pathogenesis of Alzheimer's disease and vascular dementia while increasing neuroprotective factors.

Spermidine supplementation in Alzheimer's mouse models reduced neuroinflammation, soluble amyloid beta levels, and showed promise in modulating tau pathology through cellular energy metabolism pathways.

Reviews mechanisms of impaired neurogenesis in Alzheimer's disease related to amyloid-β accumulation and tau protein tangles, proposing neurogenesis stimulation as a promising therapeutic strategy to supplement lost neurons.

Reviews how various micronutrients affect Alzheimer's pathology including β-amyloid plaques and abnormal tau protein phosphorylation, examining nutritional interventions for cognitive function improvement.

Ketone bodies from ketogenic diets may reduce neuroinflammation, improve neurotransmitter pathways, support synaptic maintenance, and reduce brain β-amyloid deposition and tau protein aggregates in Alzheimer's disease models.